Otsuka announced today that it has agreed to pay Teva $50 million and later milestone payments for the exclusive rights to develop and commercialize Fremanezumab in Japan. Fremanezumab, which targets the calcitonin gene-related peptide, is a monthly subcutaneous injection that Teva has been developing globally for the treatment of migrane, including chronic and episodic migraine, and chronic and episodic cluster headache.  According to the announcement, Otsuka will also pay royalties on revenues to Teva.